Reported Saturday, BioAge Labs Presents Preclinical Data Showing APJ Agonism Enhances Glycemic Control And Cardioprotection In Diabetic Obesity And HFpEF
Benzinga Newsdesk 1 year ago
News
Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapyData support development of next-generation
- Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy
- Data support development of next-generation APJ agonists for obesity and key comorbidities